Pharmaceutical

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients

The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.

Nov 7, 2024 - 06:00
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.
Read the original article

Tags:

Previous Article

Novo scores license to use Ascendis’ TransCon platform for $285 million

Next Article

DeepMind Nobel Prize winner says AI will have “electricity” type of impact

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BMS receives FDA approval for Opdivo to treat NSCLC

BMS receives FDA approval for Opdivo to treat NSCLC

Oct 6, 2024

FDA rejects Alvotech’s Humira biosimilar for the third time

FDA rejects Alvotech’s Humira biosimilar for the third ...

Jun 29, 2023

Opinion: Three ways to test medical AI for safety

Opinion: Three ways to test medical AI for safety

May 23, 2023